Navigation Links
eWorld Companies, Inc. Establishes Strategic Alliance With Hemophilia Foundation of Southern California
Date:2/26/2008

includes forward-looking statements concerning the future performance of our business, its operations and its financial performance and condition, and also includes selected operating results presented without the context of accompanying financial results which are not yet available. These forward-looking statements include, among others, statements with respect to our objectives and strategies to achieve those objectives, as well as statements with respect to our beliefs, plans, expectations, anticipations, estimates or intentions. These forward-looking statements are based on our current expectations. We caution that all forward-looking information is inherently uncertain and actual results may differ materially from the assumptions, estimates or expectations reflected or contained in the forward-looking information, and that actual future performance will be affected by a number of factors, including economic conditions, technological change, the integration of acquisitions, regulatory change and competitive factors, many of which are beyond our control. Therefore, future events and results may vary significantly from what we currently foresee. We are under no obligation (and we expressly disclaim any such obligation) to update or alter the forward- looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE eWorld Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Draxis Health selected by Johnson and Johnson Consumer Companies, Inc. for major contract manufacturing relationship
2. S&P: Leverage Tops Politics as Primary Credit Concern for U.S. Health Care Companies, Says S&P
3. Adult-Care.Org, After Its Initial Launch on August 28, 2007, in October 2007 Captures Attention of One of the Fastest Growing NASDAQ Companies, McCormick & Schmicks Seafood Restaurants in Marketing Partnership
4. Close Scrutiny Needed as First Stem Cell Grants Offered to For-Profit Companies, Consumers Say
5. Early Detection Push from New Alzheimers Disease Discussion Group Points to Advances by Startup Companies, Including Louisville-Based Neuronetrix, Inc.
6. LifeNet Health Establishes The Skin & Wound Allograft Institute
7. Carnegie Mellon Establishes Ray and Stephanie Lane Center for Computational Biology
8. AT&T Establishes New Network Services for Leading Medical Liability Insurer
9. Conference on Elephant Tuberculosis Research Establishes Action Plan at International Symposium on Elephant Conservation
10. Sentry Telecare Establishes Partnering Program to Market Telephone Check-in and Personal Emergency Response Service
11. Nunez Health Reform Bill Establishes Mandatory Purchase Without Linking to Subsidies for Middle Class and Poor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)...edicine is in a precipitous decline, David C. Dale...hysicians (ACP), today joined with leading repres...ll for comprehensive reforms to attract, recruit a...e physicians. , During a panel discussion of th...Dale and other panelists spoke about the challenge...
(Date:5/16/2008)...wswire/- "Huh, what did you,say?" is a phrase bein...hildren. More than 30 million Americans, that is 1...nd the numbers are growing at a dramatic rate.,Thi...me form of hearing,loss. An effort to bring more a...at led Kathlyn Maguire, who has profound hearing l...
(Date:5/16/2008)...Million for Life-threatening,Disease, BETHESDA, M...early,every state will raise funds for cystic fibr...ting in GREAT STRIDES, the largest national CF,fun... today., May is National Cystic Fibrosis Awarenes...etic disease that causes fatal lung infections and...
(Date:5/16/2008)...10,000 Sensual O Condom Packs Donation Marks the ... LOS ANGELES, May 16 /PRNewswire/ -- On Saturday, ...wn best for his hit song "Everybody in the Club,Ge...Institute (UHI) with,10,000 Sensual O Vibrating Co...ng made to promote the launch of the Association f...
Breaking Medicine News(10 mins):Health News:ACP says major system reforms needed to improve the state of primary care medicine in the US 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 3Health News:GREAT STRIDES Walks for Cystic Fibrosis Slated for 47 States This Weekend 2Health News:Everybody in the Club Scream O! 2
...eghalaya so far this year, state Health minister E... to a calling attention notice, Marak said 11 deat...South Garo, six from East Garo Hills, nine died in...hasi and Ri-Bhoi district reported three deaths. T...
...r C. Divakaran Wednesday confirmed that pig fever ...igs at a private farminwayanad//. This is believed...he country. "Pig fever was ascribed to the death ...inary Research Institute in Uttar Pradesh after sa...
...ause heat is capable of relieving pain, say resear... use of DNA technology//, scientists were able to ...ells. When the heat is on, it has a pain relievin...s of heat for pain relief on par with a pain kille...
...exander Downer has sanctioned $17 million to take ...on of HIV-AIDS//, tuberculosis and malaria. To quo...re than half a million people to be treated with a...an $1.4 million people to be treated for tuberculo...
Other Medicine News:
(Date:5/16/2008)...s Potential Biomarkers -- for Lung Cancer Diagnosi...With Cancer of Unknown Primary ...fy Cancer Types With High Sensitivity and, Speci...ment of Cancer Results of microRNA Signature to I...racy Exceeding 90% and Specificity of 99%, REHOVO...
(Date:5/15/2008)...KE, N.J., May 15 /- Eisai Corporation...m 16 clinical data abstracts about,compounds in th...nd,preclinical oncology research have been accepte...he American Society of Clinical Oncology (ASCO),t...., A wide variety of abstracts on Eisai marketed ...
(Date:5/15/2008)...Presented at ASCO Showed Acceptable Tolerability P...and 4 Neuropathy, WOODCLIFF LAKE, N.J., May 15 /P... agent eribulin mesylate (E7389) demonstrated acti...ith locally advanced or metastatic,breast cancer, ...inical,trial. The study also suggests that eribuli...
(Date:5/15/2008)... N.J., May 15 /- Sanofi-ave... that findings from the,landmark ATHENA study show...r the treatment of patients with atrial fibrillati...vascular hospitalizations or death from any,cause ... meeting the study,primary endpoint. The ATHENA re...
Breaking Medicine Technology:Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 4Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 5Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7Anxiety linked to newly diagnosed DCIS patients overestimation of breast cancer risks 11720 1Anxiety linked to newly diagnosed DCIS patients overestimation of breast cancer risks 11720 2Precancerous Breast Lesions Cause Unnecessary Worry 11716 1Precancerous Breast Lesions Cause Unnecessary Worry 11716 2Precancerous Breast Lesions Cause Unnecessary Worry 11716 3Precancerous Breast Lesions Cause Unnecessary Worry 11716 4Kaiser Permanente Approves 2429 Million in Community Benefit Grants 11713 1Kaiser Permanente Approves 2429 Million in Community Benefit Grants 11713 2Kaiser Permanente Approves 2429 Million in Community Benefit Grants 11713 3Northwestern Memorial HealthCare and Northwestern Memorial Foundation Elect New Members to Board of Directors 11709 1Northwestern Memorial HealthCare and Northwestern Memorial Foundation Elect New Members to Board of Directors 11709 2
HDL Cholesterol (PEG) Precip. Reagent + 5 ml of 50 mg/dl cholesterol std.
Cholesterol/HDL with 200 tests.
Intended for the quantitative in vitro enzymatic determination of JDL-Cholesterol in human serum or plasma. Two point reaction. Wavelength: 600 nm. Linearity: 1 to 150 mg/dL (0.03 mmol/L to 3.89 mmol
For the quantitative determination of High Density Lipoprotein in serum. Available in liquid type. Polyethylene glycol (6000) precipitating reagent. Linearity: 200 mg/dl.
Medicine Products: